Agilent's Q3 Bio-analytical Revenues Fall 8 Percent amid 27 Percent Total Revenue Decline | GenomeWeb

This article has been updated from a previous version to include information on the company's stock price.

NEW YORK (GenomeWeb News) - Agilent Technologies yesterday reported that revenues for its Bio-analytical segment declined 8 percent in its third fiscal quarter as total revenues fell 27 percent.

For the three months ended July 31, Agilent posted total revenues of $1.06 billion, a 27 percent falloff from $1.4 billion in the year-ago period but an improvement over analyst estimates of $1.02 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.